Samsung announced that it will buy French artificial intelligence company Sonio, which is developing artificial intelligence-based technology to improve medical diagnostic systems. The purchase will be made by medical equipment manufacturer Samsung Medison, a subsidiary of smartphone giant Samsung Electronics.
“The collaboration with Sonio will combine best-in-class ultrasound artificial intelligence technology and reporting capabilities, bringing a paradigm shift to prenatal ultrasound,” said Yong Kwan Kim, CEO of Samsung Medison.
Although the financial details of the transaction are not yet officially known, Samsung will acquire all of Sonio’s shares for 126 billion won (about $92 million), the AFP news agency reported, citing public financial data.
Samsung’s deal to acquire Sonio is subject to regulatory approvals
The transaction is subject to regulatory approvals, including those in France, and Sonio’s headquarters will remain in France following the acquisition. Sonio’s artificial intelligence technology uses machine learning to improve ultrasound accuracy, quality and analysis.
“In addition to working closely with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software around the world, including in underserved areas,” added Sonio CEO Cecile Brosset.
What this means for Samsung’s AI ambitions
In recent years, the utilize of AI has skyrocketed as tech giants have started incorporating AI-based tools and services into their products. Artificial intelligence has been touted to have advantages when applied to various fields such as medical care.
Sonio Detect, approved for utilize in the US, helps analyze images of the fetus, including brain and heart structures. The acquisition is Samsung’s latest move to strengthen its artificial intelligence offerings. For its part, Samsung unveiled Galaxy AI technology in its smartphones in January.
“The collaboration with Sonio will combine best-in-class ultrasound artificial intelligence technology and reporting capabilities, bringing a paradigm shift to prenatal ultrasound,” said Yong Kwan Kim, CEO of Samsung Medison.
Although the financial details of the transaction are not yet officially known, Samsung will acquire all of Sonio’s shares for 126 billion won (about $92 million), the AFP news agency reported, citing public financial data.
Samsung’s deal to acquire Sonio is subject to regulatory approvals
The transaction is subject to regulatory approvals, including those in France, and Sonio’s headquarters will remain in France following the acquisition. Sonio’s artificial intelligence technology uses machine learning to improve ultrasound accuracy, quality and analysis.
“In addition to working closely with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software around the world, including in underserved areas,” added Sonio CEO Cecile Brosset.
What this means for Samsung’s AI ambitions
In recent years, the utilize of AI has skyrocketed as tech giants have started incorporating AI-based tools and services into their products. Artificial intelligence has been touted to have advantages when applied to various fields such as medical care.
Sonio Detect, approved for utilize in the US, helps analyze images of the fetus, including brain and heart structures. The acquisition is Samsung’s latest move to strengthen its artificial intelligence offerings. For its part, Samsung unveiled Galaxy AI technology in its smartphones in January.
